Subscribe To
ITCI / Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
![Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline](https://cdn.snapi.dev/images/v1/a/c/image-1440152102-2020583.jpg)
ITCI News
![Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised](https://cdn.snapi.dev/images/v1/s/g/1981-2139613.jpg)
By Zacks Investment Research
November 3, 2023
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. more_horizontal
![Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline](https://cdn.snapi.dev/images/v1/a/c/image-1440152102-2020583.jpg)
By Seeking Alpha
August 12, 2023
Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed more_horizontal
![Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised](https://cdn.snapi.dev/images/v1/x/3/594-2007421.jpg)
By Zacks Investment Research
August 4, 2023
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. more_horizontal
![Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade) Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)](https://cdn.snapi.dev/images/v1/e/x/image-543574284-1908863.jpg)
By Seeking Alpha
May 25, 2023
Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)
Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schiz more_horizontal
![Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue? Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?](https://cdn.snapi.dev/images/v1/t/7/biotech30-1821383.jpg)
By Zacks Investment Research
March 31, 2023
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? more_horizontal
![Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up](https://cdn.snapi.dev/images/v1/j/w/biotech27-1817632.jpg)
By Zacks Investment Research
March 29, 2023
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. more_horizontal
![Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains? Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?](https://cdn.snapi.dev/images/v1/9/f/biotech13-1816601.jpg)
By Zacks Investment Research
March 29, 2023
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate re more_horizontal
![Why Intra-Cellular Therapies Climbed Tuesday Why Intra-Cellular Therapies Climbed Tuesday](https://cdn.snapi.dev/images/v1/x/0/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7261902fperson-being-comforted-during-therapyjpgopresizew400h400-1815631.jpg)
By The Motley Fool
March 28, 2023
Why Intra-Cellular Therapies Climbed Tuesday
Caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potential addition of major depressive disorder to th more_horizontal